Lantern Pharma (LTRN) Q1 2025 Earnings Transcript

Thursday, March 27, 2025 at 4:30 p.m. ET Chief Financial Officer — David Margrave Need a quote from a Motley Fool analyst? Email pr@fool.com Operator: Good morning, and welcome to our First Quarter 2025 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode. We will open the call for questions-and-answers after our management s presentation. A webcast replay of today s conference call will be available on our website at lanternpharma.com. shortly after the call. We issued a press release before the market opened today, summarizing our financial results and progress across the company for the first quarter ended March 31, 2025. A copy of this release is available through our website at lanternpharma.com, where you will also find a link to the slides management will be referencing on today s call. We would like to remind everyone that remarks about future expectations, performance, estimates, and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Lantern Pharma cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated. A number of factors could cause actual results to differ materially from those indicated by forward-looking statements, including results of clinical trials and the impact of competition. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in our annual report on Form 10-K for the year ended December 31, 2024, which is on file with the SEC and available on our website. Forward-looking statements made on this conference call are as of today, May 15, 2025, and Lantern Pharma does not intend to update any of these forward-looking statements to reflect events from circumstances that occur after today unless required by law. The webcast replay of the conference call and webinar will be available on Lantern s website. On today s webcast, we have Lantern Pharma’s CEO, Panna Sharma, and CFO, David Margrave. Panna will start things off with introductions and an overview of Lantern s strategy and business model and highlight recent achievements in our operations. After which, David will discuss our financial results. This will be followed by some concluding comments from Panna, and then we ll open the call for Q&A. I d now like to turn the call over to Panna Sharma, President and CEO of Lantern Pharma. Panna, please go ahead. Panna Sharma: Good morning. Hello, everyone. Thank you for joining us to hear about our first quarter 2025 results and corporate progress. As many of you have heard me say in the past, computational and AI-driven approaches are increasing their presence and usage at both large and emerging pharma companies for all facets of drug discovery and development. Lantern s leadership in the innovative, efficient, and pragmatic use of AI and machine learning to transform the process of developing precision oncology therapies should yield significant returns for investors and patients as our industry matures and adopts an AI centric, data first approach to drug development. The first quarter of 2025 represents a pivotal inflection point for Lantern Pharma. We ve made significant advancements across our clinical stage portfolio, while simultaneously expanding the capabilities of our proprietary radar AI platform to over 200 billion oncology focused data points. These achievements position us well for multiple value creating catalysts in the coming quarters. Let me organize today s remarks around three strategic pillars. First, our clinical pipeline progress. Second, our AI platform advancements. And third, our initiatives to maximize shareholder value. Starting with our clinical pipeline, we continue to advance multiple programs that have the potential to address significant unmet patient needs for cancer patients globally. Our Phase 1a trial for LP-184 has progressed well with enrollment now through cohort 12. We expect to complete enrollment with 62 to 65 patients across a wide range of solid tumors by the June 2025. Importantly, we re beginning to see early indications of clinical activity at higher dose levels, which aligns with our preliminary pharmacokinetic data. This quarter, our Safety Review Committee made the decision to backfill doses level 10 and 11 to ensure clarity on determining the maximum tolerated dose while maintaining patient safety. What distinguishes our synthetic lethal approach is its mechanistic precision. Unlike conventional chemotherapies and targeted agents that indiscriminately target dividing cells, LP-184 and LP-284 exploit specific genomic vulnerabilities in cancer cells, particularly those deficiencies in DNA damage repair pathways. The pharmacokinetic data from these trials suggest we re approaching concentra

Lantern Pharma (LTRN) Q1 2025 Earnings Transcript

Key takeaways

Also covered by

Lantern Pharma (LTRN) Q1 2025 Earnings Transcript

Key takeaways

Also covered by

More in business